Protagonist Therapeutics, Inc (PTGX) Operating cash flow 2016–2025
Protagonist Therapeutics, Inc (PTGX) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
$57.7MFY2025 · since FY2016: -$30.0M → $57.7M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $57.7M | -68.7% |
| FY2024 | $184.2M | +362.2% |
| FY2023 | -$70.2M | +35.0% |
| FY2022 | -$108.1M | -0.3% |
| FY2021 | -$107.9M | -48.8% |
| FY2020 | -$72.5M | -74.5% |
| FY2019 | -$41.5M | +16.9% |
| FY2018 | -$49.9M | -1390.0% |
| FY2017 | $3.9M | +112.9% |
| FY2016 | -$30.0M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More PTGX financial trends
PTGX RevenuePTGX Net incomePTGX Net marginPTGX Gross profitPTGX Gross marginPTGX Operating incomePTGX Operating marginPTGX Free cash flowPTGX Capital expendituresPTGX Return on equityPTGX Stock buybacksPTGX Dividends paidPTGX Total assetsPTGX Total liabilitiesPTGX Shareholders’ equityPTGX overview →